Why do I get anxious before my period?

Your brain handles threats differently in the second half of your cycle. Premenstrual anxiety is one of the defining experiences of the luteal phase, and there is a specific reason your brain produces it.

You may already know the shape of it: tension gathering in the week or so before bleeding starts, thoughts moving faster than you can settle them, and a sense of being braced for something that has not happened, over small things that would not normally reach you. Then, a day or two into your period, it lifts.

That rhythm is worth paying attention to, because anxiety arriving on a schedule is anxiety with a mechanism behind it, and a mechanism is something researchers can study and you can work with. The diagnostic criteria for premenstrual dysphoric disorder (PMDD) list "marked anxiety, tension, and/or feelings of being keyed up or on edge" as one of only four core affective items, any one of which can anchor a diagnosis, which means anxiety sits at the center of how the condition is defined rather than trailing behind it as a secondary complaint.

Cyclical anxiety has a different shape

What sets premenstrual anxiety apart from an anxiety disorder is remission: it builds through the second half of your cycle, clears within a few days of bleeding, and then returns on roughly the same schedule the following month.

Ko and colleagues (2013) followed 67 women with PMDD and 75 women without across three menstrual cycles, tracking depression, anxiety and irritability in both the premenstrual and follicular phases, and found that the premenstrual worsening appeared only in the PMDD group while the comparison group's experiences held steady across the cycle.

Yen and colleagues (2020) then looked at what happens when both conditions are present, and found that people with PMDD who also met criteria for generalized anxiety disorder carried their anxiety through the follicular phase as well, so it never cleared after menses. That failure to remit is what separates the two pictures.

If you have ever been handed a general anxiety diagnosis that did not quite fit, or been told your anxiety is "just PMS" and left there, this distinction is worth having, because anxiety that rises in the second half of your cycle and clears within days of bleeding is pointing at something specific enough to act on: a phase you can plan around, a pattern you can show a clinician, and a defined window where support does the most good.

The two conditions also overlap, and in that same study by Yen and colleagues 14% of the PMDD group met criteria for generalized anxiety disorder too. The authors are careful about what that means and so should we be, since the association stopped being statistically significant once they controlled for depression. Two things can be true at the same time, and working out which one is driving a given week is part of what makes treatment land better.

What is happening in your brain

Progesterone breaks down into a molecule called allopregnanolone, which acts on your brain's main calming system, and in PMDD that response appears to run in the opposite direction. Hantsoo and Epperson (2020) found that women with PMDD "did not experience ALLO-induced sedation in the luteal phase and paradoxically experienced sedation in the follicular phase," so the molecule that should settle you does something closer to the reverse.

Nguyen and colleagues (2017) found no difference in how much allopregnanolone women with PMDD actually produce, which means your body is not making the wrong amount of anything, and it explains why the most promising approaches are not about adding or removing a hormone but about changing how your brain responds to the hormones you already have.

That is an encouraging place to land, because response is modifiable in a way that hormone levels are not. Bäckström and colleagues (2021) tested the idea directly in 206 women across 12 European centers, using a compound designed to block allopregnanolone's action, and while it narrowly missed statistical significance on its primary outcome, distress scores did improve compared with placebo. The biology is solid enough to build medicines from, and the first attempt told researchers that the target needs refining rather than replacing. Our PMDD guide goes deeper into this mechanism.

The regulation system you can work with

Your prefrontal cortex sits behind your forehead and does much of the work of regulating emotional responses, including damping down the amygdala when it flags a threat, so that you notice something worrying without it taking over. It is also the part of the system that responds to training, which is why most of the current research effort is pointed at it.

Ironside and colleagues (2019), publishing in JAMA Psychiatry, tested whether stimulating the prefrontal cortex could strengthen that regulation, and found that in people with trait anxiety, prefrontal stimulation reduced the amygdala's response to threatening faces. The scale is worth knowing, since 16 participants in a single session makes this a promising proof of concept rather than a settled result, and the kind of finding that justifies building larger trials on top of it.

Where the evidence stands

Safety is well established. Antal and colleagues (2026), writing for the European Society for Brain Stimulation and the International Federation for Clinical Neurophysiology, report no stimulation-related serious adverse events across more than 300,000 sessions, and the mild effects that do occur, tingling, headache and fatigue, are often reported by people receiving placebo stimulation as well. For a technology being weighed up alongside medication, that record counts for a good deal.

The anxiety evidence is younger than the depression evidence, and it shows. Zheng and colleagues (2024) pooled 56 randomized placebo-controlled trials in Translational Psychiatry, and while the effect on depression came through clearly, the pooled anxiety result landed at p = 0.051, just short of the conventional threshold for statistical significance. The anxiety literature they had to work with was half the size of the depression literature and built from smaller trials, which is a reason the picture remains unresolved rather than a verdict on the technology itself.

Other reviews reach different conclusions, and Xie and colleagues (2024) pooled 15 trials in anxiety disorders and found significant benefit, including for generalized anxiety disorder. Reviews in this field disagree with each other, and reporting that disagreement honestly is more useful to you than picking whichever one flatters us.

What our own research shows. Nettle™ is clinically validated for the management of pain and mood associated with menstruation in the UK and EU, and we have also just completed a trial in PMDD in which anxiety was one of the outcomes we measured.

In that placebo-controlled trial, run by Prof Paul Faulkner at Queen Mary University of London, 82.4% of participants reduced their anxiety by more than 30% on the GAD-7 scale. The result is in peer review now, and it is the most encouraging signal we have.

The variable this research has been missing

Ovarian hormones change more than mood, because they also change the electrical properties of your cortex. Schloemer and colleagues (2020) tracked 15 women across four points in the cycle, taking blood hormone measurements alongside brain measurements, and found that intracortical excitability differed significantly between the lowest and highest estrogen points.

They change how your brain responds to stimulation as well. Lee and colleagues (2018) tested 14 women twice, once in the early follicular phase when estrogen is low and once mid-luteal when it is higher, and found the response was larger when estrogen was elevated, concluding that heightened responses occur with elevated estrogen in a way that points to hormone-related variability in stimulation outcomes.

That was 14 women in what its own authors call a preliminary study, measuring a brain marker rather than how anyone felt, but the implication is hard to ignore, and Rudroff and colleagues (2020) spell it out when they recommend that people enrolled in repeated-session stimulation studies be stimulated during the same phase of their menstrual cycle.

Most brain stimulation research has not done this, which means decades of trials have averaged across a variable that changes the result, and the effects reported so far may well be diluted versions of what is achievable once timing is accounted for.

Our PMDD trial delivered stimulation in the late luteal phase, the window when premenstrual anxiety peaks, rather than at whatever point in the cycle a participant happened to start, so timing was a design decision rather than an afterthought.

What you can do now

Start documenting the pattern, because two cycles of dated notes will tell you more than any article can, and a dated record is what a diagnosis needs. Tracking will not resolve premenstrual anxiety on its own, though it makes everything that follows work better. You can use the Samphire app to track experiences and create custom ones to paint a picture of your cycle.

Then bring it to a clinician, since the options with the strongest evidence behind them, from SSRIs through to therapy, are prescribed rather than bought, and our PMDD guide covers those in full. Brain stimulation belongs in that conversation as one option among several, sitting alongside your existing care rather than in place of it.

Where this is going

Premenstrual anxiety was dismissed for a long time, first as a personality trait and then as a hormonal inevitability, and neither explanation survived contact with the evidence. What the research now describes is a specific, timed and measurable change in the way the brain regulates threat, and being measurable is what makes something treatable.

The work is unfinished, but the direction is clear, the safety record is strong, and the variable that has been missing from decades of brain stimulation research is the one your body supplies every month.

If you want the fuller picture of PMDD, including how it is diagnosed and the full range of treatment options, read our guide to PMDD symptoms, diagnosis and treatment - What Is PMDD? Understanding Symptoms, Causes, and Evidence-Based Treatment Options.